Johnson & Johnson: A Dividend Aristocrat You Must Neither Sell Nor Buy At These Prices

  • Johnson & Johnson has over 50 years of track record of regular dividend payments.
  • The company currently faces stagnation as well as a hostile regulatory environment.
  • Johnson & Johnson has a strong product pipeline, expects to release over 10 products by 2021.
  • At current high levels, there’s no sense in selling, or buying, JNJ.

By S. Mitra, with inputs from Dr UKM

We are beginning a series of 10 articles on 10 blue chip dividend aristocrats, some, if not all, of which are must-haves in any proper biotech portfolio. In today's article, I will cover Johnson & Johnson (JNJ), and then follow up with the following list. I will discuss pros and cons of each investment as a dividend. At the end of the series, I will sum it all up by giving an order to the stocks - best to worst as dividend stocks.

The full post is available to investor members only. Subscribe here.